ci 994 has been researched along with Adenocarcinoma in 4 studies
tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells
tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine maximum tolerated dose of CI-994, a novel oral histone deacetylase inhibitor, in combination with carboplatin and paclitaxel in patients with advanced solid tumors." | 2.71 | Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. ( Cunningham, C; Grove, W; Kraker, A; Nemunaitis, J; Olivares, J; Olson, S; Pauer, LR; Williams, A, 2004) |
| " Following treatment mice were evaluated for pharmacodynamic effects as well as the pharmacokinetic behavior of CI-994 and the de-acetylated derivative dinaline." | 1.30 | Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline). ( Corbett, TH; Foster, BJ; Jones, L; LoRusso, PM; Wiegand, R, 1997) |
| "Treatment with salicylanilide, CI-940, mimosine, aphidicolin, quercetin or ciclopirolxalamine, which, like CI-994, block cells in the G1-S phase of the cell cycle, did not affect the production of this protein." | 1.29 | Role of a small molecular weight phosphoprotein in the mechanism of action of CI-994 (N-acetyldinaline). ( Hook, KE; Klohs, WD; Kraker, AJ; Rummel, SA; Steinkampf, RW, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pauer, LR | 1 |
| Olivares, J | 1 |
| Cunningham, C | 1 |
| Williams, A | 1 |
| Grove, W | 2 |
| Kraker, A | 1 |
| Olson, S | 1 |
| Nemunaitis, J | 1 |
| Richards, DA | 1 |
| Boehm, KA | 1 |
| Waterhouse, DM | 1 |
| Wagener, DJ | 1 |
| Krishnamurthi, SS | 1 |
| Rosemurgy, A | 1 |
| Macdonald, K | 1 |
| Gulyas, S | 1 |
| Clark, M | 1 |
| Dasse, KD | 1 |
| Rummel, SA | 1 |
| Kraker, AJ | 1 |
| Steinkampf, RW | 1 |
| Hook, KE | 1 |
| Klohs, WD | 1 |
| Foster, BJ | 1 |
| Jones, L | 1 |
| Wiegand, R | 1 |
| LoRusso, PM | 1 |
| Corbett, TH | 1 |
2 trials available for ci 994 and Adenocarcinoma
| Article | Year |
|---|---|
Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors.
Topics: Acetylation; Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy | 2004 |
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2006 |
2 other studies available for ci 994 and Adenocarcinoma
| Article | Year |
|---|---|
Role of a small molecular weight phosphoprotein in the mechanism of action of CI-994 (N-acetyldinaline).
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzamides; Cell Cycle; Cell Nucleus; Colonic Neopla | 1995 |
Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline).
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Area Under Curve; Benzamides; Blood Cell Count; Bone | 1997 |